INVESTINGDow Ends Sharply Lower; Trade War Escalation Slams StocksBy Rob LenihanMay 13, 2019 4:08 PM EDT
EARNINGSOpioid Maker Insys Sinks After Saying It May Be Forced to File BankruptcyBy Tony OwusuMay 13, 2019 9:55 AM EDT
INVESTINGInsys Therapeutics Founder Convicted in Opioid Bribery Scheme: ReportBy Rob LenihanMay 2, 2019 4:08 PM EDT
STOCKSOpioid makers continue to rise in spite of potential Trump-directed lawsuitsBy Tony OwusuAug 16, 2018 3:02 PM EDT
STOCKSFDA Approval Of GW Pharma's Cannabis-Based Drug Marks MilestoneBy Alexander NicollJun 27, 2018 9:00 AM EDT
POLITICSChina Pledges Help With Fentanyl Imports; Says U.S. Must Curb Opioid DemandBy Bill MeagherJun 25, 2018 3:15 PM EDT
HEALTHNovartis Signs Agreement With Canadian Cannabis Company Tilray Regarding Med PotBy Bill MeagherMar 21, 2018 5:57 PM EDT
STOCKSThe Hottest Investing Plays in the Booming Weed Industry for 2018By Kinsey GrantFeb 16, 2018 8:00 PM EST
REGULATIONCalifornia Cannabis Growers Celebrate New Year's Day as Weed Goes LegalBy Ellen ChangJan 1, 2018 8:40 AM EST
JIM CRAMERAugust's Inexplicable Selloffs Are Here: Cramer's 'Mad Money' RecapBy Scott RuttAug 18, 2017 6:23 AM EDT
HEALTHBiotech Movers: Alder Shares Drop Despite Positive Data for Migraine Prevention DrugBy Armie Margaret LeeJun 27, 2017 9:31 AM EDT
HEALTHDepomed, Insys Shares Down After FDA Decision on Endo's Opana ERBy Melissa AngellJun 9, 2017 5:20 PM EDT
ETFsLaunch of cannabis ETF may not be best option for investorsBy Ellen ChangJun 6, 2017 12:57 PM EDT
HEALTHBiotech Movers: Array Shares Rise on Bristol-Myers CollaborationBy Armie Margaret LeeMay 30, 2017 9:29 AM EDT
JIM CRAMERRaytheon, Celgene, Orbital ATK, CenturyLink: 'Mad Money' Lightning RoundBy Scott RuttMay 17, 2017 6:32 AM EDT
JIM CRAMERIt's Hard to Find Winners and Stick With Them: Cramer's 'Mad Money' RecapBy Scott RuttMay 17, 2017 6:15 AM EDT
STOCKSAnalysts' Actions -- Allergan, Coach, General Dynamics, Occidental and MoreBy TheStreet StaffMay 10, 2017 9:29 AM EDT
